The Pharma Data
OCTOBER 21, 2020
and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. About ViiV Healthcare.
The Pharma Data
JANUARY 20, 2021
The CytomX clinical-stage pipeline includes potentially first-in-class product candidates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
FEBRUARY 22, 2022
He began his oncology development career at Rhône Poulenc Rorer Inc. In 1999, he joined the Aventis Group as Senior Director, Oncology Global Clinical Development. In 2005, he was appointed Senior Director of Oncology at Johnson & Johnson and in 2006, Executive Director of Oncology at Schering-Plough.
The Pharma Data
NOVEMBER 9, 2020
Image: Copyright © 2009-2020 Merck Sharp & Dohme Corp., It is very clear that in this study, the addition of ipilimumab did not add clinical benefit but did add toxicity. a subsidiary of Merck & Co., Kenilworth, N.J., All rights reserved. Merck , also known as MSD outside of the U.S.
The Pharma Data
NOVEMBER 11, 2020
McChesney entered the private sector in 1996 as the vice president of development at NaPro BioTherapeutics Inc., In 2009, he established Ironstone Separations Inc., departing in 2003 to become the chief scientific officer for Tapestry Pharmaceuticals and ChromaDex Inc.
Drug Target Review
SEPTEMBER 26, 2023
1-4 This approach saves time, money, and resources, and ultimately leads to safer medicines going forward to the clinic. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. 2009 Sep;14(17–18):876–84.
The Pharma Data
AUGUST 1, 2021
The approval by the Food and Drug Administration (FDA) was based on efficacy and safety data from the Saphnelo clinical development programme, including two TULIP Phase III trials and the MUSE Phase II trial. The option for Medarex to co-promote the product expired on its acquisition by Bristol-Myers Squibb (BMS) in 2009.
Expert insights. Personalized for you.
52 
Let's personalize your content